Updates are available Correction dated 2022-04-21
Click to view Correction: https://doi.org/10.1186/s13063-022-06266-0
-
Authors
Halford, Sarah https://orcid.org/0000-0002-8110-9766
Wan, Susan
Dragoni, Ilaria
Silvester, Julie
Nazarov, Bobojon
Anthony, Daniel
Anthony, Suzie
Ladds, Emma
Norrie, John
Dhaliwal, Kevin
,
-
Funding
Funding for this research was provided by:
LifeArc
- License Information
-
More Information
Article History
Received: 22 January 2021
Accepted: 15 July 2021
First Online: 19 August 2021
Change Date: 21 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13063-022-06266-0
Declarations
:
: North West -Liverpool Central Research Ethics Committee (REC reference: 20/NW/0278), 18 June 2020, I certify that this trial has received appropriate ethical approval as described above.Consent to participation in the trial will be obtained from all participants entering into the SPIKE-1 trial.
: Unpublished PK data has been removed from Section 3.2 of the CRUKD/20/002 protocol to allow for publication. The data removed cannot be disclosed under the terms of contractual agreements in place between the Sponsor (Cancer Research UK) and Ono Pharmaceutical Co., Ltd.
: The authors declare that they have no competing interests.
